Ann: GenScript Further Pre-Clinical Validation for Phase II Trial, page-45

Well done Bucky! The share price has broken through its all time low only a month after the company issued a most impressive final first phase clinical report for its leading anti-cancer drug that was tested against resistant cancers. Most drug development companies would be flying high after news like this, but your constant white anting on irrelevant rubbish like the type of pills that are needed and other insignificant issues for the last two years has paid off by sowing the seeds of doubt in the subconsciousness of investors who are now frightened of the slightest boo. Whatever your motives, whether commercial or personal, well done Bucky and friends. Enjoy!